Investor Relations
About Us
Scope Fluidics S.A., a constituent of the sWIG80 and WIGmed stock market indices, is a life science company engaged in developing cutting-edge technologies for the medical diagnostics and healthcare markets. It has demonstrated its global potential by completing the largest transaction to date in the Polish life science sector: the sale of the PCR|ONE system to US-based Bio-Rad Laboratories for a total of USD 130 million. Scope Fluidics operates under a Venture Studio model – identifying worldwide challenges and market opportunities, and transforming them into concepts for breakthrough products. Its focus lies in healthcare, where it applies a rigorous process for selecting and developing projects with strong commercial prospects globally. The Company’s strategy is to create value by bringing projects to maturity and executing strategic transactions, including sales to international medtech operators. Its most advanced project currently under development is BACTEROMIC, a rapid, automated Antibiotic Susceptibility Testing (AST) system, which provides precise, actionable insights to guide the selection of effective antibiotic therapies, combining high performance with ease of use. Results from the Early Access Programme (EAP) confirm both the system’s readiness for broader market launch and its significant competitive advantages. In addition, the Scope Fluidics Group is advancing two early-stage projects: 1) EDOCERA – a system designed for the rapid diagnosis of stroke, enabling immediate medical intervention, and 2) HYBOLIC – a system intended for the early detection of metabolic syndrome risks, including insulin resistance and type 2 diabetes, by monitoring key biomarkers such as insulin and glucose levels.
Strategy and Business Model
Every project begins with the identification of unmet needs in the life science sector. Next, Scope Fluidics develops an innovative solution that is subject to ongoing technical and commercial validation from the very outset of the project. The development is driven by a dedicated team of in-house experts and scientists with knowledge spanning microbiology, biochemistry, manufacturing, physics, IT, and engineering. Collaboration with external specialists can further strengthen this process. Projects are developed within special-purpose vehicles (SPVs), controlled by Scope Fluidics. A new concept originates at the Company and, once it is ready to advance, an SPV is established to carry the project forward. The original team members transfer to the SPV, ensuring continuity of expertise and vision. As the project progresses, the team expands in line with its growing needs. From conception through execution, development is collaborative and solution-focused, addressing challenges at every stage of the process. The ultimate goal is a strategic sale. The target model involves the transfer of all shares in the SPV along with its assets – including intellectual property, certifications, and technology. However, the Company remains flexible as to the timing of the sale, allowing for staged commercialisation if appropriate. Strategic transactions are expected to generate value for shareholders through the payment of dividends. By following this model, Scope Fluidics ensures that proven methodologies, best practices, and processes can be leveraged across multiple projects, enhancing operational efficiency. This approach also maximises the chance of success for subsequent ventures.
Strategy and Business Model
Every project begins with the identification of unmet needs in the life science sector. Next, Scope Fluidics develops an innovative solution that is subject to ongoing technical and commercial validation from the very outset of the project. The development is driven by a dedicated team of in-house experts and scientists with knowledge spanning microbiology, biochemistry, manufacturing, physics, IT, and engineering. Collaboration with external specialists can further strengthen this process. Projects are developed within special-purpose vehicles (SPVs), controlled by Scope Fluidics. A new concept originates at the Company and, once it is ready to advance, an SPV is established to carry the project forward. The original team members transfer to the SPV, ensuring continuity of expertise and vision. As the project progresses, the team expands in line with its growing needs. From conception through execution, development is collaborative and solution-focused, addressing challenges at every stage of the process. The ultimate goal is a strategic sale. The target model involves the transfer of all shares in the SPV along with its assets – including intellectual property, certifications, and technology. However, the Company remains flexible as to the timing of the sale, allowing for staged commercialisation if appropriate. Strategic transactions are expected to generate value for shareholders through the payment of dividends. By following this model, Scope Fluidics ensures that proven methodologies, best practices, and processes can be leveraged across multiple projects, enhancing operational efficiency. This approach also maximises the chance of success for subsequent ventures.
Funding
Scope Fluidics manages each project only during its early stages, up to the point when it is transferred for execution to a dedicated special-purpose vehicle (SPV). However, the Management Board remains unchanged, with identical representation at both the Company and its SPVs, ensuring aligned leadership and oversight. Project funding is secured both by Scope Fluidics and by the SPVs. The Company raises capital through equity offerings and debt financing, including facilities provided by the European Investment Bank. The SPVs, in turn, seek to access grants and subsidies. Scope Fluidics also plays a key role in attracting external investors to acquire partial or full ownership stakes in the SPVs. Project teams within the respective subsidiaries are also actively involved in this process.
Intellectual Property
One of the core strengths of Scope Fluidics and its Group lies in consistent and proactive protection of intellectual and industrial property related to their developed innovations. Currently, the Company holds a patent for elements of its proprietary microfluidic technology, as well as four registered trademarks. In addition, each subsidiary independently manages and protects its own industrial property portfolio. Bacteromic Sp. z o.o., for instance, maintains five patent families, which collectively include two granted patents and ten pending patent applications, safeguarding the company’s technological solutions. A patent family is defined as a collection of individually protected elements within a given solution – such as specific components of a cartridge or analyser, ensuring comprehensive protection.
Our Companies
BACTEROMIC – Unique diagnostic solutions
BACTEROMIC is a diagnostic system designed to address one of the most pressing challenges in modern medicine – that of antimicrobial resistance. The system enables phenotypic assessment of the effectiveness of antibiotics used to treat various infections, such as those affecting the respiratory tract, bloodstream, urinary tract, or skin. It also has the capability to detect resistance mechanisms, providing clinicians with deeper insight into bacterial behaviour and treatment options. Thanks to the determination and expertise of a multidisciplinary team of biotechnologists, engineers and software developers – combined with an innovative approach to contemporary diagnostics – Scope Fluidics has created a device with enormous market potential, one that can revolutionise antibiotic therapy. Each test simultaneously analyses 640 independent bacterial cultures, offering unmatched diagnostic power in a single run.
EDOCERA
EDOCERA is developing a cutting-edge system for real-time stroke prevention and diagnosis. The solution combines a monitoring device with AI-powered software that continuously tracks a patient’s vital health parameters. Using sophisticated algorithms, the system detects critical changes that indicate a heightened risk of stroke and immediately issues an alert. By shortening reaction times, EDOCERA enables faster initiation of appropriate treatment, thereby reducing the severity of long-term consequences of stroke. This innovation not only improves patient safety but also brings peace of mind to individuals at risk and their families.
HYBOLIC
HYBOLIC is focused on developing a next-generation system for the early detection of diabetes and related metabolic disorders. The solution is intended integrate a biomarker monitoring device with intelligent software that will analyse concentrations of key molecules, such as glucose and insulin. With the aid of advanced algorithms, the system aims to identify early warning signals of insulin resistance, potentially years before symptoms appear. By enabling earlier diagnosis, HYBOLIC will support proactive health management and empower users to take informed steps to protect their metabolic well-being. Early detection improves treatment outcomes and allows the implementation of effective preventive strategies. Ultimately, HYBOLIC will help users maintain better control over their health, enhancing both safety and quality of life.
OUR TEAM
Scope Fluidics brings together a diverse team of highly-skilled professionals with expertise spanning biochemistry, microbiology, physics, engineering, law, marketing, business development, finance, human resources, and project management. The Group’s strategic direction is set by a three-member Management Board, whose composition reflects the Company’s dual commitment to scientific excellence and sound business leadership.
Piotr Garstecki
President of the Board
Co-founder of Scope Fluidics. Professor of chemistry and manager. He has led scientific and technical projects in Poland and the United States, specializing in soft matter physics and microfluidic techniques. Passionate about organizational development and value creation through the development of technologies that solve important problems in healthcare.
Marcin Izydorzak
Vice President of the Management Board
Co-founder of Scope Fluidics. Manager. He gained experience in technology companies, scientific institutes, and pharmaceutical companies. In his professional career, he coordinated a number of implementation processes. Enthusiast of risk management and solving difficult problems. At Scope Fluidics, he is responsible for clinical trials, intellectual property, production, and registration processes.
Szymon Ruta
Vice President of the Management Board – Chief Financial Officer
A manager with many years of experience in managing capital groups, executing M&A transactions, and cooperating with the capital market, including raising capital from international institutions. At Scope Fluidics, he is responsible for the finance division, M&A transactions, and investor relations.
Robert Przytuła
Chairman of the Supervisory Board
Graduate of the Faculty of Mathematics, Mechanics, and Computer Science at the University of Warsaw – major: Applications of Mathematics in Finance and Economics. After graduation, he joined the Investment Advisory Department at BGŻ S.A. Brokerage House in August 1998, and has been working as a stock analyst since early 2000. In 2000, he completed postgraduate studies in Financial and Management Accounting. From June 2003 to September 2008, he worked at Skarbiec TFI S.A., initially as a stock analyst and later as Director of the Analysis Department. Since March 2009, he has been a managing partner of the TOTAL FIZ fund.
Andrzej Chądzyński
Member of the Supervisory Board
A manager with many years of experience in the international medical device market. Responsible for, among other things: product and market development in the medical imaging division, co-creating strategic plans, preparing and evaluating M&A projects (Business Development Manager Imaging Division), management of the international medical imaging contrast media division (Business Unit Manager Contrast Media), financial and management controlling of the medical imaging division (approx. EUR 700 million in annual turnover), creation and improvement of the management information system, co-creation and control of the implementation of financial plans (5-year, annual, quarterly), operational and financial management of companies in Poland, the Czech Republic, and Hungary (President of the Management Board of the company in Poland, Finance & Operations Manager Region East Europe), conducting, among other things, business unit demerger processes.
Robert Hołyst
Member of the Supervisory Board
Professor Robert Hołyst is Head of the Soft Matter Department at the Institute of Physical Chemistry of the Polish Academy of Sciences. He spent over six years working in the USA (University of Washington), France (Ecole Normale Superieure), and Germany (Max Planck Institute in Mainz). He has supervised and mentored 30 doctoral students and over 30 postdoctoral fellows (eight of whom are now professors in Poland, the USA, and China). He is the author of over 290 articles in the fields of physics, chemistry, biology, and biotechnology published in English-language journals, three academic textbooks, and over 40 patents (including in the USA). He has conducted research for large corporations, including Unilever, Samsung, and Mitsui Chemicals. In 2003-2004, he was a shareholder and CEO of Advanced Science and Technology Investment Group Sp. z.o.o. He has experience in managing large projects (approximately 40 between 1993 and 2021), including four European Union projects: NOBLESSE (€3.8 million), ERA CHAIR (€2.5 million), NAMeS (€2.5 million), PD2PI (€2.5 million), the NCBiR project (PLN 4.5 million), a TEAM grant from the Foundation for Polish Science (PLN 3 million), and two MAESTRO grants from the National Science Centre (PLN 3 million each). He has lectured at Harvard, MIT, Yale, Princeton, five Max Planck Institutes, Ecole Normale in Paris and Lyon, Tokyo University, Samsung Advanced Institute of Technology, etc. He created the Dream Chemistry Award and the Gold Medal for Chemistry, both of which are recurring competitions. Between 2007 and 2015, he reorganized the Institute of Physical Chemistry of the Polish Academy of Sciences, increasing the effectiveness of research and project revenues more than tenfold.
Patryk Mikucki
Member of the Supervisory Board
A leader with nearly 20 years of experience in research and development in the pharmaceutical industry. Vice President of Clinical Research at Alexion, responsible for creating the model and national clinical research departments around the world. Previously, he worked for AstraZeneca for 17 years. As Vice President of AstraZeneca Pharma Poland, he was involved in the creation and responsible for the dynamic growth of the AstraZeneca Clinical Research Operations Center in Warsaw. As Regional Director (Europe) for Research and Development, he managed national Clinical Research departments in over 20 European countries. From the beginning of his career, he gained experience working in local and global units of the company, including in Sweden, Germany, and Ukraine. Patryk Mikucki is a graduate of the Faculty of Veterinary Medicine in Lublin with a PhD in veterinary science. He is the author of several scientific publications in this field. He is also a graduate of the Warsaw-Illinois Executive MBA program.
Karolina Radziszewska
Member of the Supervisory Board
Karolina Radziszewska has over 20 years of professional experience, including HR management in large international companies. She specializes in increasing employee engagement and productivity in companies undergoing significant organizational changes, including mergers and acquisitions, rapid organic growth, and restructuring. Karolina Radziszewska is Vice President of Human Resources at Skanska’s office company for Central and Eastern Europe. Before joining Skanska, she was People Director at ConsenSys. Previously, as HR Director and member of the Management Board at Randstad, she was responsible for HR strategy and processes at the EMEA level. She also gained experience at companies such as PwC, ZA Puławy, and Hewitt Associates. Karolina Radziszewska holds a master’s degree in economics from the Warsaw School of Economics.
Joanna Rzempała
Member of the Supervisory Board
Joanna Rzempała holds a PhD in economics. She is an assistant professor at the Department of Organization and Management of the Faculty of Economics, Finance, and Management at the University of Szczecin. She lectures on project management. She holds the title of Certified Senior Project Manager IPMA-B, a certificate from the Minister of Finance for accounting services, and PRINCE2 Foundation and GPM project management certificates. She is a member of financial committees and program councils in Poland and abroad. She serves as Vice President of the Board of the International Project Management Association Poland.
Professor Carl Wittwer
A global pioneer in molecular diagnostics – one of the creators of PCR technology, currently affiliated with the University of Utah Medical School (USA). He is one of the most important authorities in the field of molecular diagnostics technology. In the 1990s, he developed the first polymerase chain reaction system that enabled genetic material to be identified in less than 15 minutes. He is the author of numerous publications and scientific studies that inspire developers of diagnostic devices around the world.
Professor Wilhelm Huck
An expert in microfluidics, synthetic cell construction, and the development of methods for determining reaction rates in individual cells. He conducted postdoctoral research at Harvard University and was also director of an institute at the University of Cambridge. He is currently the head of a research group at Radboud University in the Netherlands. He collaborates with many industrial partners to develop droplet microfluidics for single-cell analysis. He is a co-founder of the Cambridge-based biotechnology company Sphere Fluidics and a member of the Advisory Board of the Australian Institute for Bioengineering and Nanotechnology.
Sarai Kemp
Dr Vincent Linder
Professor David Weitz
Professor of physics at Harvard University, one of the most cited physicists in the world. He works in the fields of soft matter physics, polymers, and microfluidics. He has created many modern technologies, contributing significantly to the development of single-cell sequencing technology. He has many years of experience working in industry. He is the co-founder of 20 technology startups, including in the fields of life sciences and medical diagnostics.
Dr Agnieszka Sulikowska
OUR AWARDS
The company has won numerous awards confirming its innovation and effectiveness:
During the 7th Polish Capital Congress, organised by Forbes Polska magazine, Scope Fluidics was awarded the title of “Stock Exchange Company of the Year 2022”.
The company also won the Bulls and Bears Award from Parkiet Stock Exchange and Investors’ Daily in the category “NewConnect Market Company of the Year 2022”.
Prof. Piotr Garstecki – co-founder, one of the largest shareholders and president of the management board of Scope Fluidics S.A. – received an award in the “International Expansion” category in the prestigious EY Entrepreneur of the Year competition in 2024.
The CEO of Scope Fluidics also took third place in the 2022 Polish Business Leaders Ranking prepared by Forbes Poland magazine.
Newsletter
Stay up to date with the latest information.